Bacteriological and clinical studies on biapenem

Yoshiro Sawae, Kaoru Okada, Teruhisa Otsuka, Hiroyasu Misumi, Nobuyuki Shimono, Katsuhiko Eguchi, Yoshiyuki Niho, Kiyoshi Ninomiya, Yukio Kumagai, Koji Takaki, Ikuo Sumita, Takatoshi Inoue, Takanori Toshima

Research output: Contribution to journalArticle

Abstract

We performed bacteriological and clinical studies on biapenem (BIPM), a new parenteral carbapenem antibiotic, with the following results. 1. Antibacterial activity The MICs of BIPM against various clinical isolates were determined with an inculum size of 106 cells/ml. The MIC90 was 0.2μg/ml for methicillin-sensitive Staphylococcus aureus (MSSA), 100 for methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus faecalis, 0.78 for Escherichia coil, Klebsiella pneumoniae and Citrobacter freundii, 1.56 for Enterobacter spp., 3.13 for Proteus spp., and 12.5 for Pseudomonas aeruginosa. Its activity against gram-positive cocci was almost the same as meropenem (MEPM), and less than imipenem (IPM) and panipenem (PAPM). Its activity against gram-negative rods was less than MEPM, but almost the same as PAPM, more potent than IPM. 2. Clinical efficacy Two patients with acute bronchitis, 9 with pneumonia, 6 with chronic respiratory tract infection, 1 with sepsis, and 3 with pyelonephritis were treated with BIPM at a daily dose of 300∼600mg for 3∼22days. Clinical response was excellent in 2, good in 17, fair in 1 and unknown in 3 patients. The causative organisms were all eradicated. Eruption was seen in one patient, and elevation of RBC, Ht, basophil, eosinophil, GOT and ALP were noted in 3 patients.

Original languageEnglish
Pages (from-to)381-390
Number of pages10
JournalCHEMOTHERAPY
Volume42
DOIs
Publication statusPublished - Jan 1 1994

Fingerprint

biapenem
meropenem
Imipenem
Citrobacter freundii
Escherichia
Gram-Positive Cocci
Enterobacter
Proteus
Carbapenems
Methicillin
Basophils
Bronchitis
Enterococcus faecalis
Pyelonephritis
Klebsiella pneumoniae
Methicillin-Resistant Staphylococcus aureus
Cell Size
Eosinophils
Respiratory Tract Infections
Pseudomonas aeruginosa

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Cite this

Sawae, Y., Okada, K., Otsuka, T., Misumi, H., Shimono, N., Eguchi, K., ... Toshima, T. (1994). Bacteriological and clinical studies on biapenem. CHEMOTHERAPY, 42, 381-390. https://doi.org/10.11250/chemotherapy1953.42.Supplement4_381

Bacteriological and clinical studies on biapenem. / Sawae, Yoshiro; Okada, Kaoru; Otsuka, Teruhisa; Misumi, Hiroyasu; Shimono, Nobuyuki; Eguchi, Katsuhiko; Niho, Yoshiyuki; Ninomiya, Kiyoshi; Kumagai, Yukio; Takaki, Koji; Sumita, Ikuo; Inoue, Takatoshi; Toshima, Takanori.

In: CHEMOTHERAPY, Vol. 42, 01.01.1994, p. 381-390.

Research output: Contribution to journalArticle

Sawae, Y, Okada, K, Otsuka, T, Misumi, H, Shimono, N, Eguchi, K, Niho, Y, Ninomiya, K, Kumagai, Y, Takaki, K, Sumita, I, Inoue, T & Toshima, T 1994, 'Bacteriological and clinical studies on biapenem', CHEMOTHERAPY, vol. 42, pp. 381-390. https://doi.org/10.11250/chemotherapy1953.42.Supplement4_381
Sawae, Yoshiro ; Okada, Kaoru ; Otsuka, Teruhisa ; Misumi, Hiroyasu ; Shimono, Nobuyuki ; Eguchi, Katsuhiko ; Niho, Yoshiyuki ; Ninomiya, Kiyoshi ; Kumagai, Yukio ; Takaki, Koji ; Sumita, Ikuo ; Inoue, Takatoshi ; Toshima, Takanori. / Bacteriological and clinical studies on biapenem. In: CHEMOTHERAPY. 1994 ; Vol. 42. pp. 381-390.
@article{8c90553f0cf049f8a7f003f63396d376,
title = "Bacteriological and clinical studies on biapenem",
abstract = "We performed bacteriological and clinical studies on biapenem (BIPM), a new parenteral carbapenem antibiotic, with the following results. 1. Antibacterial activity The MICs of BIPM against various clinical isolates were determined with an inculum size of 106 cells/ml. The MIC90 was 0.2μg/ml for methicillin-sensitive Staphylococcus aureus (MSSA), 100 for methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus faecalis, 0.78 for Escherichia coil, Klebsiella pneumoniae and Citrobacter freundii, 1.56 for Enterobacter spp., 3.13 for Proteus spp., and 12.5 for Pseudomonas aeruginosa. Its activity against gram-positive cocci was almost the same as meropenem (MEPM), and less than imipenem (IPM) and panipenem (PAPM). Its activity against gram-negative rods was less than MEPM, but almost the same as PAPM, more potent than IPM. 2. Clinical efficacy Two patients with acute bronchitis, 9 with pneumonia, 6 with chronic respiratory tract infection, 1 with sepsis, and 3 with pyelonephritis were treated with BIPM at a daily dose of 300∼600mg for 3∼22days. Clinical response was excellent in 2, good in 17, fair in 1 and unknown in 3 patients. The causative organisms were all eradicated. Eruption was seen in one patient, and elevation of RBC, Ht, basophil, eosinophil, GOT and ALP were noted in 3 patients.",
author = "Yoshiro Sawae and Kaoru Okada and Teruhisa Otsuka and Hiroyasu Misumi and Nobuyuki Shimono and Katsuhiko Eguchi and Yoshiyuki Niho and Kiyoshi Ninomiya and Yukio Kumagai and Koji Takaki and Ikuo Sumita and Takatoshi Inoue and Takanori Toshima",
year = "1994",
month = "1",
day = "1",
doi = "10.11250/chemotherapy1953.42.Supplement4_381",
language = "English",
volume = "42",
pages = "381--390",
journal = "CHEMOTHERAPY",
issn = "0009-3165",

}

TY - JOUR

T1 - Bacteriological and clinical studies on biapenem

AU - Sawae, Yoshiro

AU - Okada, Kaoru

AU - Otsuka, Teruhisa

AU - Misumi, Hiroyasu

AU - Shimono, Nobuyuki

AU - Eguchi, Katsuhiko

AU - Niho, Yoshiyuki

AU - Ninomiya, Kiyoshi

AU - Kumagai, Yukio

AU - Takaki, Koji

AU - Sumita, Ikuo

AU - Inoue, Takatoshi

AU - Toshima, Takanori

PY - 1994/1/1

Y1 - 1994/1/1

N2 - We performed bacteriological and clinical studies on biapenem (BIPM), a new parenteral carbapenem antibiotic, with the following results. 1. Antibacterial activity The MICs of BIPM against various clinical isolates were determined with an inculum size of 106 cells/ml. The MIC90 was 0.2μg/ml for methicillin-sensitive Staphylococcus aureus (MSSA), 100 for methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus faecalis, 0.78 for Escherichia coil, Klebsiella pneumoniae and Citrobacter freundii, 1.56 for Enterobacter spp., 3.13 for Proteus spp., and 12.5 for Pseudomonas aeruginosa. Its activity against gram-positive cocci was almost the same as meropenem (MEPM), and less than imipenem (IPM) and panipenem (PAPM). Its activity against gram-negative rods was less than MEPM, but almost the same as PAPM, more potent than IPM. 2. Clinical efficacy Two patients with acute bronchitis, 9 with pneumonia, 6 with chronic respiratory tract infection, 1 with sepsis, and 3 with pyelonephritis were treated with BIPM at a daily dose of 300∼600mg for 3∼22days. Clinical response was excellent in 2, good in 17, fair in 1 and unknown in 3 patients. The causative organisms were all eradicated. Eruption was seen in one patient, and elevation of RBC, Ht, basophil, eosinophil, GOT and ALP were noted in 3 patients.

AB - We performed bacteriological and clinical studies on biapenem (BIPM), a new parenteral carbapenem antibiotic, with the following results. 1. Antibacterial activity The MICs of BIPM against various clinical isolates were determined with an inculum size of 106 cells/ml. The MIC90 was 0.2μg/ml for methicillin-sensitive Staphylococcus aureus (MSSA), 100 for methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus faecalis, 0.78 for Escherichia coil, Klebsiella pneumoniae and Citrobacter freundii, 1.56 for Enterobacter spp., 3.13 for Proteus spp., and 12.5 for Pseudomonas aeruginosa. Its activity against gram-positive cocci was almost the same as meropenem (MEPM), and less than imipenem (IPM) and panipenem (PAPM). Its activity against gram-negative rods was less than MEPM, but almost the same as PAPM, more potent than IPM. 2. Clinical efficacy Two patients with acute bronchitis, 9 with pneumonia, 6 with chronic respiratory tract infection, 1 with sepsis, and 3 with pyelonephritis were treated with BIPM at a daily dose of 300∼600mg for 3∼22days. Clinical response was excellent in 2, good in 17, fair in 1 and unknown in 3 patients. The causative organisms were all eradicated. Eruption was seen in one patient, and elevation of RBC, Ht, basophil, eosinophil, GOT and ALP were noted in 3 patients.

UR - http://www.scopus.com/inward/record.url?scp=0028587556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028587556&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.42.Supplement4_381

DO - 10.11250/chemotherapy1953.42.Supplement4_381

M3 - Article

VL - 42

SP - 381

EP - 390

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

ER -